Guggenheim Capital’s Meridian Bioscience Inc VIVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-24,380
| Closed | -$810K | – | 2060 |
|
|
2022
Q4 | $810K | Buy |
24,380
+17,415
| +250% | +$561K | 0.01% | 1267 |
|
|
2022
Q3 | $220K | Buy |
+6,965
| New | +$226K | ﹤0.01% | 1763 |
|
|
2021
Q4 | – | Sell |
-12,375
| Closed | -$238K | – | 2267 |
|
|
2021
Q3 | $238K | Sell |
12,375
-10,086
| -45% | -$201K | ﹤0.01% | 2005 |
|
|
2021
Q2 | $498K | Sell |
22,461
-1,618
| -7% | -$34.3K | ﹤0.01% | 1834 |
|
|
2021
Q1 | $632K | Sell |
24,079
-20,861
| -46% | -$496K | ﹤0.01% | 1611 |
|
|
2020
Q4 | $840K | Buy |
+44,940
| New | +$839K | 0.01% | 1424 |
|
|
2019
Q3 | – | Sell |
-25,729
| Closed | -$305K | – | 2174 |
|
|
2019
Q2 | $305K | Sell |
25,729
-16,334
| -39% | -$197K | ﹤0.01% | 1858 |
|
|
2019
Q1 | $741K | Sell |
42,063
-1,045
| -2% | -$17.4K | 0.01% | 1520 |
|
|
2018
Q4 | $749K | Sell |
43,108
-14,647
| -25% | -$250K | 0.01% | 1500 |
|
|
2018
Q3 | $860K | Buy |
57,755
+868
| +2% | +$13.5K | 0.01% | 1693 |
|
|
2018
Q2 | $904K | Buy |
56,887
+16,239
| +40% | +$242K | 0.01% | 1662 |
|
|
2018
Q1 | $578K | Buy |
40,648
+14,757
| +57% | +$218K | ﹤0.01% | 2326 |
|
|
2017
Q4 | $364K | Sell |
25,891
-11,358
| -30% | -$166K | ﹤0.01% | 2440 |
|
|
2017
Q3 | $533K | Buy |
37,249
+14,496
| +64% | +$207K | ﹤0.01% | 2369 |
|
|
2017
Q2 | $360K | Sell |
22,753
-7,372
| -24% | -$106K | ﹤0.01% | 2508 |
|
|
2017
Q1 | $417K | Sell |
30,125
-11,061
| -27% | -$155K | ﹤0.01% | 2439 |
|
|
2016
Q4 | $729K | Sell |
41,186
-11,512
| -22% | -$202K | ﹤0.01% | 2285 |
|
|
2016
Q3 | $1.02M | Sell |
52,698
-3,089
| -6% | -$60.5K | ﹤0.01% | 2078 |
|
|
2016
Q2 | $1.09M | Sell |
55,787
-17,678
| -24% | -$347K | ﹤0.01% | 1996 |
|
|
2016
Q1 | $1.51M | Sell |
73,465
-12,983
| -15% | -$256K | ﹤0.01% | 1772 |
|
|
2015
Q4 | $1.77M | Sell |
86,448
-5,932
| -6% | -$114K | 0.01% | 1700 |
|
|
2015
Q3 | $1.58M | Sell |
92,380
-10,342
| -10% | -$189K | ﹤0.01% | 1768 |
|
|
2015
Q2 | $1.91M | Buy |
102,722
+13,795
| +16% | +$256K | ﹤0.01% | 1817 |
|
|
2015
Q1 | $1.7M | Buy |
88,927
+9,691
| +12% | +$179K | ﹤0.01% | 1917 |
|
|
2014
Q4 | $1.3M | Sell |
79,236
-2,149
| -3% | -$36.9K | ﹤0.01% | 2052 |
|
|
2014
Q3 | $1.44M | Sell |
81,385
-2,087
| -3% | -$41K | ﹤0.01% | 2001 |
|
|
2014
Q2 | $1.72M | Buy |
83,472
+4,036
| +5% | +$82.9K | ﹤0.01% | 1932 |
|
|
2014
Q1 | $1.73M | Buy |
79,436
+495
| +0.6% | +$11.3K | ﹤0.01% | 1891 |
|
|
2013
Q4 | $2.1M | Buy |
78,941
+1,601
| +2% | +$39.4K | 0.01% | 1746 |
|
|
2013
Q3 | $1.83M | Buy |
77,340
+10,281
| +15% | +$240K | 0.01% | 1675 |
|
|
2013
Q2 | $1.44M | Buy |
+67,059
| New | +$1.45M | 0.01% | 1750 |
|
Other funds holding VIVO
Guggenheim Capital's VIVO Position: Q1 2023 in Review
Guggenheim Capital sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 24,380 shares — an estimated $810K sold.
Guggenheim Capital first reported a position in VIVO in Q2 2013 and held it in 31 quarters. The position peaked at $2.1M in Q4 2013. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.
- Guggenheim Capital reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
- Guggenheim Capital sold 24,380 Meridian Bioscience Inc shares in Q1 2023, an estimated $810K.
- Guggenheim Capital first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 31 quarters.
- Guggenheim Capital's Meridian Bioscience Inc position peaked at $2.1M in Q4 2013.
- 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.
Based on Guggenheim Capital's 13F filing for Q1 2023, filed 11 May 2023.